The new management has continued with paid ghost-written articles and likely the social medial pumping. "Investor relations" Vendors - NP used nearly a dozen outside stock pumpers that did paid ghost written articles and social medial stock pumping. Deceptive and something SEC and DOJ still have more action.Ĥ.
CYDY YAHOO CONVERSATION TRIAL
Kelly's misrepresenting of the Phase 1 trial data buy muddling compassionate care, Basket and Phase 1 mTNBC trial data together. Kelly's insider trading where his wife sold substantial share after unblinded data and before public release of the data.ģ.
CoV - still to come by has some inclusion in the NP indictment for misrepresenting the CD-12 trial results. HIV - looks to have completed this stage with indictments, fines and clawbacks of ill-gotten gains.Ģ. The CYDY SEC filing identified several issues they were investigating:ġ. This is only the first stage of the SEC/DOJ investigations. Here’s hoping we don’t see CytoDyn on our 2023 list."ĭidn't even get to the DOJ indictment of the former CEO. Still, CytoDyn has vowed to plow on with other HIV indications for the monoclonal antibody as well as nonalcoholic steatohepatitis and metastatic triple-negative breast cancer.
:max_bytes(150000):strip_icc()/001_delete-email-from-conversation-yahoo-1174446-4156170730ab4d0f99676b70a0b35d58.jpg "cydy yahoo conversation")
The biotech was hoping to get an FDA nod for leronlimab as a combination therapy in HIV that is resistant to antiretroviral therapy. In October, the company withdrew an application for a very specific HIV indication, blaming the CRO responsible for the studies that underpinned the filing.ĬytoDyn said the application for approval had to be withdrawn due to “systemic issues” with the quality of data the CRO overseeing the study captured.
While the company finally ditched the COVID-19 indication, the trouble for leronlimab in the lead indication of HIV continued. After earning a spot on our 2021 list for a bizarre year that included touting lead drug leronlimab despite its abject failure and getting publicly smacked down by the FDA for it, CytoDyn continues its bizarre trajectory in biotech infamy. We promise we don’t like picking on CytoDyn, but it continues to rain crushed tomatoes over the company. They selected Cytodyn as one of their worst 10 of the year: Review of the worst biotechs of 2022 by Fierce Biotech, one of the biotech trade magazines. In October, CytoDyn ( OTCQB:CYDY) said it was withdrawing the leronlimab BLA.Pourhassan was terminated as CEO in January 2022.
CYDY YAHOO CONVERSATION LICENSE
The indictment further alleges that in in April 2020, after CytoDyn ( OTCQB:CYDY) missed timelines, Pourhassan told Kazempour to submit the Biologics License Application, even if it was not complete, so that Pourhassan and CytoDyn ( OTCQB:CYDY) could tell investors that the BLA was submitted.Pouhassan and Kazem Kazempou, CEO of a private company that ran CytoDyn's ( OTCQB:CYDY) trials, are accused of misleading investors about the timeline and status of leronlimab regulatory submissions to the US FDA in an effort to to artificially boost the price of the company's stock.The stock is down ~12% in Tuesday afternoon trading.Nader Pourhassan, the former CEO of embattled biotech CytoDyn ( OTCQB:CYDY), has been indicted by a federal court grand jury and accused of conspiracy to defraud investors in regards to the company's HIV candidate leronlimab.
0 kommentar(er)
